|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | CXCR4 is a Prog?nostic Marker in Acute Myelogenous Leukemia显示文摘 | Spoo A C Lubbert M Wierda W G | 2007 | Blood2007，109，2： | 1 |
| 2 | Long-term results of the fludarabine, eyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia 显示文摘 | Tam CS O'Brien S Wierda W el al | 2008 | Blood2008，112，4： | 1 |
| 3 | Long-term results of the flu-darabine, cyclophosphamide,and rituxiraab regimen as initial therapy ofchronic lymphocytic leukemia显示文摘 | Tam C S O' Brien S Wierda W | 2008 | Blood2008，112，4： | 1 |
| 4 | Long-term results of the fludarabine,cyclophosphamide,and rituximab regimen as initial therapy of chronic lymphocytic leukemia显示文摘 | TAM C S O'BRIEN S WIERDA W | 2008 | Blood2008，112，： | 1 |
| 5 | Chemoimmunotherapy with fludarabine,cyclophosphamide,and rituximab for relapsed and refractory chronic lymphocytic leukemia显示文摘 | Wierda W O Brien S Wen S | | 0，，： | 1 |
| 6 | lmmunogenicity of biop- harmaceuticals in laboratory animals显示文摘 | Wierda D Smith H W Zwick C M | 2001 | Toxicology2001，158，12： | 1 |
| 7 | Long-term results of the fludarabine,cyclophosphamide,and rituximab regimen as initial therapy of chronic lymphocytic leukemia显示文摘 | Tam CS O'Brien S Wierda W | 2008 | Blood2008，112，4： | 1 |
| 8 | Ofatumumab as single-agent CD20immunotherapy in fludarabine-refractory chronic lymphocytic leukemia显示文摘 | WIERDA W G KIPPS T J MAYER J | 2010 | J Clin Oncol2010，28，： | 1 |
| 9 | Pneumonia during remission induction chemotherapy in patients with acute leukemia显示文摘 | Garcia JB Lei X Wierda W | 2013 | Ann Am Thorac Soc2013，10，5： | 1 |
| 10 | Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows iden- tification of epigenetically repressed molecular pathways with clin- ical impact 显示文摘 | Tong W G Wierda W G Lin E | 2010 | Epigeneties2010，5，6： | 1 |
| 11 | Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinu- tuzurnab into clinical practice 显示文摘 | SANFORD D S WIERDA W G BURGER J A | 2015 | Clin Lymph Myelom Leuk2015，15，7： | 1 |
| 12 | Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia显示文摘 | Wierda W G O'Brien S Wang X | 2007 | Blood2007，109，11： | 1 |
| 13 | A phase 1 and pharrnacodynamic study of AT9283, a small-molecule inhibitor of Aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis 显示文摘 | Foran J Ravandi F Wierda W | 2014 | Clin Lymphoma Myeloma Leuk2014，14，3： | 1 |
| 14 | CARs in chronic lympho- cytic leukemia-ready to drive显示文摘 | Hosing C Kebriaei P Wierda W | 2013 | Curt Hematol Malig Rep2013，8，1： | 1 |
| 15 | Long-term re- suits of the fludarabine, eyclophosphamide, and rituximabregimen as initial therapy of chronic lymphocytic leu- kemia 显示文摘 | Tam CS O' Brien S Wierda W | 2008 | Blood2008，112，4： | 1 |
| 16 | Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab: incidence and predictors显示文摘 | Borthakur G O'Brien S Wierda W G | 2007 | Br J Haematol2007，136，1： | 1 |
| 17 | AT- 101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance 显示文摘 | BALAKRISHNAN K BURGER J A WIERDA W G | 2009 | Blood2009，113，1： | 1 |
| 18 | Go- ssypol,a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells 显示文摘 | BALAKRISHANA K WIERDA W G KEATING M J | 2008 | Blood2008，112，： | 1 |
| 19 | Chemoimmunotherapy with fludarabine, cyclophosphamide,and rimximab for relapsed and refractory chronic lymphocytic leukemia显示文摘 | Wierda W O'Brien S Wen S | 2005 | J Clin Oncol2005，23，18： | 1 |
| 20 | Mechanism of action of SNS-032, a novel cyclin- dependent kinase inhibitor, in chronic lymphocytic leukemia 显示文摘 | CHEN R WIERDA W G CHUBB S | 2009 | Blood2009，113，19： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员